CA2886991A1 - Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs - Google Patents
Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs Download PDFInfo
- Publication number
- CA2886991A1 CA2886991A1 CA2886991A CA2886991A CA2886991A1 CA 2886991 A1 CA2886991 A1 CA 2886991A1 CA 2886991 A CA2886991 A CA 2886991A CA 2886991 A CA2886991 A CA 2886991A CA 2886991 A1 CA2886991 A1 CA 2886991A1
- Authority
- CA
- Canada
- Prior art keywords
- ibs
- bacterial antigen
- level
- antigen antibody
- markers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003630 histaminocyte Anatomy 0.000 title claims description 153
- 244000005700 microbiome Species 0.000 title description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 claims abstract description 371
- 239000000523 sample Substances 0.000 claims abstract description 242
- 238000000034 method Methods 0.000 claims abstract description 165
- 238000003745 diagnosis Methods 0.000 claims abstract description 56
- 108091007433 antigens Proteins 0.000 claims description 414
- 102000036639 antigens Human genes 0.000 claims description 414
- 239000000427 antigen Substances 0.000 claims description 409
- 230000001580 bacterial effect Effects 0.000 claims description 351
- 239000003550 marker Substances 0.000 claims description 172
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 110
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 102
- 239000012634 fragment Substances 0.000 claims description 86
- 239000002771 cell marker Substances 0.000 claims description 80
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 60
- 229960001340 histamine Drugs 0.000 claims description 56
- 241000588724 Escherichia coli Species 0.000 claims description 54
- 229960002986 dinoprostone Drugs 0.000 claims description 54
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 53
- 229960000890 hydrocortisone Drugs 0.000 claims description 51
- 241000589875 Campylobacter jejuni Species 0.000 claims description 50
- 230000000890 antigenic effect Effects 0.000 claims description 44
- 108010079246 OMPA outer membrane proteins Proteins 0.000 claims description 40
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 38
- 238000007619 statistical method Methods 0.000 claims description 32
- 239000012472 biological sample Substances 0.000 claims description 30
- 238000007477 logistic regression Methods 0.000 claims description 28
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 239000002438 stress hormone Substances 0.000 claims description 22
- 238000001514 detection method Methods 0.000 claims description 20
- 241000607762 Shigella flexneri Species 0.000 claims description 19
- 101000851240 Homo sapiens Elongation factor Tu, mitochondrial Proteins 0.000 claims description 18
- 102100033238 Elongation factor Tu, mitochondrial Human genes 0.000 claims description 17
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 16
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 16
- 206010010774 Constipation Diseases 0.000 claims description 16
- 229940076279 serotonin Drugs 0.000 claims description 16
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 claims description 15
- 206010012735 Diarrhoea Diseases 0.000 claims description 15
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 15
- 229960000258 corticotropin Drugs 0.000 claims description 15
- 241001468157 Lactobacillus johnsonii Species 0.000 claims description 11
- 241000605861 Prevotella Species 0.000 claims description 10
- 241000193468 Clostridium perfringens Species 0.000 claims description 4
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims description 3
- 241000421809 Brisaster fragilis Species 0.000 claims 1
- 241000495778 Escherichia faecalis Species 0.000 claims 1
- 238000012896 Statistical algorithm Methods 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 abstract description 8
- 239000013068 control sample Substances 0.000 abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 136
- 150000001413 amino acids Chemical group 0.000 description 111
- 102000004196 processed proteins & peptides Human genes 0.000 description 98
- 229920001184 polypeptide Polymers 0.000 description 95
- 108090000623 proteins and genes Proteins 0.000 description 78
- 102000004169 proteins and genes Human genes 0.000 description 78
- 235000018102 proteins Nutrition 0.000 description 77
- 238000003556 assay Methods 0.000 description 57
- 241000894006 Bacteria Species 0.000 description 54
- 108010040721 Flagellin Proteins 0.000 description 52
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 45
- 210000002966 serum Anatomy 0.000 description 42
- 208000024891 symptom Diseases 0.000 description 35
- 201000010099 disease Diseases 0.000 description 33
- 239000007790 solid phase Substances 0.000 description 27
- 241000588722 Escherichia Species 0.000 description 26
- 241000736262 Microbiota Species 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 25
- 238000010647 peptide synthesis reaction Methods 0.000 description 25
- 108020004707 nucleic acids Proteins 0.000 description 24
- 102000039446 nucleic acids Human genes 0.000 description 24
- 150000007523 nucleic acids Chemical class 0.000 description 24
- 238000000746 purification Methods 0.000 description 24
- 238000003259 recombinant expression Methods 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 18
- 238000004422 calculation algorithm Methods 0.000 description 18
- 229940015062 campylobacter jejuni Drugs 0.000 description 17
- 230000002496 gastric effect Effects 0.000 description 17
- 239000000090 biomarker Substances 0.000 description 16
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 15
- 239000000758 substrate Substances 0.000 description 14
- -1 BONE Chemical compound 0.000 description 13
- 101800000414 Corticotropin Proteins 0.000 description 13
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 13
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 13
- 238000012544 monitoring process Methods 0.000 description 13
- 201000003379 Townes-Brocks syndrome Diseases 0.000 description 12
- 241000606124 Bacteroides fragilis Species 0.000 description 11
- 241000194032 Enterococcus faecalis Species 0.000 description 11
- 241000208202 Linaceae Species 0.000 description 11
- 235000004431 Linum usitatissimum Nutrition 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 10
- 238000007637 random forest analysis Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 9
- 241000186779 Listeria monocytogenes Species 0.000 description 9
- 238000001574 biopsy Methods 0.000 description 9
- 208000011231 Crohn disease Diseases 0.000 description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000002700 urine Anatomy 0.000 description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 239000013024 dilution buffer Substances 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 208000028774 intestinal disease Diseases 0.000 description 7
- 230000000670 limiting effect Effects 0.000 description 7
- 238000004020 luminiscence type Methods 0.000 description 7
- 238000010801 machine learning Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000015943 Coeliac disease Diseases 0.000 description 6
- 241000607768 Shigella Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 244000005709 gut microbiome Species 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 5
- 108010074051 C-Reactive Protein Proteins 0.000 description 5
- 102100032752 C-reactive protein Human genes 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 241001112696 Clostridia Species 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 241000611831 Prevotella sp. Species 0.000 description 5
- 102000001400 Tryptase Human genes 0.000 description 5
- 108060005989 Tryptase Proteins 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 230000007149 gut brain axis pathway Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 210000004877 mucosa Anatomy 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000002864 sequence alignment Methods 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 101710094518 4-aminobutyrate aminotransferase Proteins 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 241000589876 Campylobacter Species 0.000 description 4
- 241000193403 Clostridium Species 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 241001112693 Lachnospiraceae Species 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 208000008275 microscopic colitis Diseases 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 4
- 229960003040 rifaximin Drugs 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000000405 serological effect Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 206010000159 Abnormal loss of weight Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 241001646716 Escherichia coli K-12 Species 0.000 description 3
- 101000821449 Homo sapiens Secreted and transmembrane protein 1 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 241000186781 Listeria Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102100021853 Secreted and transmembrane protein 1 Human genes 0.000 description 3
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001387 anti-histamine Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 210000003495 flagella Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000013610 patient sample Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000003938 response to stress Effects 0.000 description 3
- 238000013179 statistical model Methods 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 238000012706 support-vector machine Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 2
- 101710115046 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 108091005471 CRHR1 Proteins 0.000 description 2
- 108091005470 CRHR2 Proteins 0.000 description 2
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241001464956 Collinsella Species 0.000 description 2
- 102100038018 Corticotropin-releasing factor receptor 1 Human genes 0.000 description 2
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 101710111023 GTPase Obg/CgtA Proteins 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 101710164702 Major outer membrane protein Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 101000992168 Porphyromonas gingivalis (strain ATCC BAA-308 / W83) Outer membrane protein 40 Proteins 0.000 description 2
- 101710194807 Protective antigen Proteins 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010038063 Rectal haemorrhage Diseases 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 description 2
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 238000012084 abdominal surgery Methods 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000003431 anti-prostaglandin Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 241000395146 bacterium A4 Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003150 biochemical marker Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229940041967 corticotropin-releasing hormone Drugs 0.000 description 2
- KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 108010028610 formyl-coenzyme A transferase Proteins 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 238000007392 microtiter assay Methods 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 210000004760 visceral afferent Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108030001082 (S)-3-amino-2-methylpropionate transaminases Proteins 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 102000002572 Alpha-Globulins Human genes 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 241001135756 Alphaproteobacteria Species 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241001135755 Betaproteobacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000186560 Blautia coccoides Species 0.000 description 1
- 101100447653 Caenorhabditis elegans phg-1 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102100026096 Claudin-8 Human genes 0.000 description 1
- 241001443882 Coprobacillus Species 0.000 description 1
- 241001464948 Coprococcus Species 0.000 description 1
- 241000192700 Cyanobacteria Species 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 241001135761 Deltaproteobacteria Species 0.000 description 1
- 244000182625 Dictamnus albus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 241001143779 Dorea Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241001148568 Epsilonproteobacteria Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017367 Frequent bowel movements Diseases 0.000 description 1
- 241001453172 Fusobacteria Species 0.000 description 1
- 241000192128 Gammaproteobacteria Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102000006485 Glutamyl Aminopeptidase Human genes 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100449532 Homo sapiens CXCL1 gene Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 description 1
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000005712 Keratin-8 Human genes 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000928987 Lachnospiraceae bacterium A4 Species 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
- 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 108700002045 Nod2 Signaling Adaptor Proteins 0.000 description 1
- 101150083031 Nod2 gene Proteins 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- 108700028353 OmpC Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000480383 Prevotella sp. oral taxon 472 str. F0295 Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710201515 Putative aminopeptidase Proteins 0.000 description 1
- 101710156978 Ras-like protein Proteins 0.000 description 1
- 241000691806 Rhinobatos productus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 102000013674 S-100 Human genes 0.000 description 1
- 108700021018 S100 Proteins 0.000 description 1
- 101100348089 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) BUR6 gene Proteins 0.000 description 1
- 241001138501 Salmonella enterica Species 0.000 description 1
- 101100173866 Shigella flexneri fliC gene Proteins 0.000 description 1
- 101000579490 Solanum lycopersicum Suberization-associated anionic peroxidase 1 Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 101710126110 Surface protein F Proteins 0.000 description 1
- 102000003141 Tachykinin Human genes 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000008234 Toll-like receptor 5 Human genes 0.000 description 1
- 108010060812 Toll-like receptor 5 Proteins 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 1
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 241000985257 [Clostridium] cocleatum Species 0.000 description 1
- 241001531188 [Eubacterium] rectale Species 0.000 description 1
- 241001464870 [Ruminococcus] torques Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 230000000356 anti-lactoferrin effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000009388 chemical precipitation Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 108090000239 claudin 8 Proteins 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 210000002049 efferent pathway Anatomy 0.000 description 1
- 229940096118 ella Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010003342 flaB flagellin Proteins 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000010243 gut motility Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 241000514897 mixed subtypes Species 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- CMPQUABWPXYYSH-UHFFFAOYSA-N phenyl phosphate Chemical compound OP(O)(=O)OC1=CC=CC=C1 CMPQUABWPXYYSH-UHFFFAOYSA-N 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 108060008037 tachykinin Proteins 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- OOLLAFOLCSJHRE-ZHAKMVSLSA-N ulipristal acetate Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(OC(C)=O)C(C)=O)[C@]2(C)C1 OOLLAFOLCSJHRE-ZHAKMVSLSA-N 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710574P | 2012-10-05 | 2012-10-05 | |
| US61/710,574 | 2012-10-05 | ||
| US201361871853P | 2013-08-29 | 2013-08-29 | |
| US61/871,853 | 2013-08-29 | ||
| PCT/IB2013/059045 WO2014053996A2 (en) | 2012-10-05 | 2013-10-01 | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2886991A1 true CA2886991A1 (en) | 2014-04-10 |
Family
ID=49447585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2886991A Abandoned CA2886991A1 (en) | 2012-10-05 | 2013-10-01 | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for ibs |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10184940B2 (https=) |
| EP (1) | EP2904395B1 (https=) |
| JP (1) | JP6329553B2 (https=) |
| CN (1) | CN104884959B (https=) |
| AU (1) | AU2013326133B2 (https=) |
| CA (1) | CA2886991A1 (https=) |
| MX (1) | MX360479B (https=) |
| SG (2) | SG11201502641YA (https=) |
| WO (1) | WO2014053996A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0720250D0 (en) * | 2007-10-17 | 2007-11-28 | Univ Edinburgh | Immunogenic compositions containing escherichia coli h7 flagella and methods of use thereof |
| BR112015027591A2 (pt) * | 2013-05-17 | 2017-07-25 | Basf Se | processos para a preparação de um ácido, de um cloreto e de um composto de sulfimina |
| SG11201509371XA (en) * | 2013-05-24 | 2015-12-30 | Nestec Sa | Pathway specific markers for diagnosing irritable bowel syndrome |
| AU2016349703A1 (en) | 2015-11-06 | 2018-11-01 | Vetica Labs, Inc. | Methods of detecting inflammatory markers and treating inflammatory conditions in companion animals |
| EP3421616A1 (en) * | 2017-06-29 | 2019-01-02 | Tata Consultancy Services Limited | Method and system for monitoring the gut health of an individual |
| AU2018346255A1 (en) * | 2017-10-03 | 2020-04-23 | Seres Therapeutics, Inc. | Manipulation of tryptamine metabolism |
| JP6533930B1 (ja) * | 2018-08-23 | 2019-06-26 | 一般社団法人日本農業フロンティア開発機構 | 疾病評価指標算出方法、装置、システム、及び、プログラム、並びに、疾病評価指標を算出するためのモデル作成方法。 |
| US11884958B2 (en) | 2019-04-30 | 2024-01-30 | Mayo Foundation For Medical Education And Research | Assessing and treating functional gastrointestinal disorders |
| WO2025071560A1 (en) * | 2023-09-28 | 2025-04-03 | Rutgers, The State University Of New Jersey | Methods of diagnosing b cell malignancies, detecting b cell malignancy relapse, and treating thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004048600A2 (en) * | 2002-11-22 | 2004-06-10 | Emory University | Diagnostic tests and methods for diagnosing inflammatory bowel disease |
| US20060154276A1 (en) * | 2004-05-13 | 2006-07-13 | Prometheus Laboratories Inc. | Methods of diagnosing inflammatory bowel disease |
| US7943328B1 (en) * | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
| US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| US20080085524A1 (en) | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
| CN102480932B (zh) * | 2009-09-01 | 2015-01-14 | 阿昂梅迪克斯公司 | 源于肠道共生细菌的细胞外小泡及利用其的疫苗、备选药物筛选方法 |
| PH12012500850A1 (en) * | 2009-10-30 | 2013-01-07 | Prometheus Laboratories Inc | Methods for diagnosing irritable bowel syndrome |
-
2013
- 2013-10-01 CA CA2886991A patent/CA2886991A1/en not_active Abandoned
- 2013-10-01 SG SG11201502641YA patent/SG11201502641YA/en unknown
- 2013-10-01 JP JP2015535149A patent/JP6329553B2/ja not_active Expired - Fee Related
- 2013-10-01 EP EP13779635.5A patent/EP2904395B1/en not_active Not-in-force
- 2013-10-01 AU AU2013326133A patent/AU2013326133B2/en not_active Expired - Fee Related
- 2013-10-01 SG SG10201702773QA patent/SG10201702773QA/en unknown
- 2013-10-01 WO PCT/IB2013/059045 patent/WO2014053996A2/en not_active Ceased
- 2013-10-01 MX MX2015004271A patent/MX360479B/es active IP Right Grant
- 2013-10-01 CN CN201380063446.2A patent/CN104884959B/zh not_active Expired - Fee Related
-
2015
- 2015-03-30 US US14/673,660 patent/US10184940B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104884959B (zh) | 2017-12-01 |
| JP2015533213A (ja) | 2015-11-19 |
| MX2015004271A (es) | 2015-08-14 |
| JP6329553B2 (ja) | 2018-05-23 |
| WO2014053996A3 (en) | 2014-05-30 |
| EP2904395A2 (en) | 2015-08-12 |
| US20150346200A1 (en) | 2015-12-03 |
| WO2014053996A2 (en) | 2014-04-10 |
| CN104884959A (zh) | 2015-09-02 |
| SG10201702773QA (en) | 2017-06-29 |
| HK1213050A1 (en) | 2016-06-24 |
| EP2904395B1 (en) | 2018-09-05 |
| MX360479B (es) | 2018-11-05 |
| AU2013326133B2 (en) | 2019-07-04 |
| AU2013326133A1 (en) | 2015-04-23 |
| US10184940B2 (en) | 2019-01-22 |
| SG11201502641YA (en) | 2015-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10184940B2 (en) | Antibodies to microbiome, stress factors and mast cell markers as diagnostic markers for IBS | |
| US10338083B2 (en) | Pathway specific markers for diagnosing irritable bowel syndrome | |
| US20140219966A1 (en) | Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with clostridium difficile disease | |
| JP2013534313A (ja) | 腸の炎症状態の生物学的マーカーとしてのｈｍｇｂ１の使用、糞便サンプル中のｈｍｇｂ１を検出するための非侵襲法およびそのキット | |
| JP2017531801A (ja) | 炎症性腸疾患及びセリアック病から過敏性腸症候群を識別するための方法及びシステム | |
| JP2020106537A (ja) | 心臓障害のマーカーとしての１３＋／１７＋ｂｉｎ１発現 | |
| JP6193976B2 (ja) | バイオマーカーとしてのクロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）・デヒドロゲナーゼおよび毒素 | |
| HK1213050B (en) | Antibodies to microbiome as diagnostic markers for ibs | |
| RU2572717C1 (ru) | Способ иммунодиагностики заболеваний, вызванных helicobacter pylori-инфекцией | |
| JP7740807B2 (ja) | 敗血症原因細菌の免疫学的分析方法及び該方法に用いるモノクローナル抗体 | |
| US20250271428A1 (en) | Peptide-based biomarkers and related aspects for disease detection | |
| Bayoumy et al. | Antivinculin antibodies as a marker of irritable bowel syndrome–diarrhea in Egyptian patients | |
| JP2024522606A (ja) | 機能性消化管障害のための診断マーカー | |
| NZ701004B2 (en) | Clostridium difficile dehydrogenase and toxin as a biomarker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20161004 |
|
| FZDE | Discontinued |
Effective date: 20201207 |